[Form 4] OPKO HEALTH, INC. Insider Trading Activity

Rhea-AI Filing Summary

OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D., reported multiple open-market purchases of OPKO common stock. On 11/21/2025, he bought blocks of 102,371, 3,894, 89,375, 191,490 and 192,870 shares at prices ranging from $1.30 to $1.335 per share. After these transactions, one line shows 216,706,448 shares of common stock beneficially owned indirectly as indicated in footnote (1). Separate lines show 3,568,951 shares held directly and 30,127,177 shares held indirectly as described in footnote (2).

Footnote (1) explains that certain shares are held by Frost Gamma Investments Trust and related entities, and footnote (2) explains holdings in Frost Nevada Investments Trust and related entities. In both cases, the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

Insights

Equity Ownership & Governance Analyst

Large insider, who is CEO, Chairman and 10% owner, increased indirect holdings by 580,000 shares through affiliated trusts.

The filing reports that **Phillip Frost, M.D.**, who serves as **CEO, Chairman and 10% owner** of **OPKO Health, Inc.**, purchased common stock on 11/21/2025. Five open-market "P" transactions show acquisitions totaling 580,000 shares at prices between $1.30 and $1.335 per share. After these transactions, one indirect holding line shows **216,706,448** shares, with additional separate positions of **3,568,951** shares held directly and **30,127,177** shares held indirectly.

The filing explains a layered ownership structure involving **Frost Gamma Investments Trust**, **Frost Gamma L.P.**, **Frost Gamma, Inc.**, **Frost-Nevada Corporation**, and **Frost Nevada Investments Trust**. In each case, the reporting person disclaims beneficial ownership beyond any pecuniary interest, which is standard language when interests are held through partnerships and trusts. This means the economic exposure exists through these entities, while legal and reporting control follows the described roles.

The key item to watch is the scale of the reported beneficial ownership across direct and indirect holdings, given the role as CEO, Chairman and 10% owner. Future Forms 4 will show whether this ownership level continues to rise, fall, or remain stable over time, especially around or after 11/21/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		P		102,371	A	$1.3	216,228,819	I	See Footnote(1)
Common Stock	11/21/2025		P		3,894	A	$1.32	216,232,713	I	See Footnote(1)
Common Stock	11/21/2025		P		89,375	A	$1.325	216,322,088	I	See Footnote(1)
Common Stock	11/21/2025		P		191,490	A	$1.33	216,513,578	I	See Footnote(1)
Common Stock	11/21/2025		P		192,870	A	$1.335	216,706,448	I	See Footnote(1)
Common Stock								3,568,951	D
Common Stock								30,127,177	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

1. Name and Address of Reporting Person^*

Frost Gamma Investments Trust

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

2. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

	Phillip Frost, M.D., Individually and as Trustee	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.